Key Highlights
- Capricor Therapeutics shares closed up 58% at $6.65.
- The FDA will evaluate supplemental deramiocel efficacy results for Duchenne muscular dystrophy.
- The move may push back the August 22 PDUFA deadline.
- The update significantly reduces immediate regulatory hurdles for the lead candidate.
Capricor Therapeutics (NASDAQ: CAPR) shares closed up 58% at $6.65 following news that the FDA will evaluate supplemental deramiocel efficacy results for Duchenne muscular dystrophy.
What Happened
The move may push back the August 22 PDUFA deadline while significantly reducing immediate regulatory hurdles and clarifying the path forward for the company's lead candidate.
Market Reaction
Shares surged sharply as investors responded to the reduced regulatory uncertainty, viewing the FDA's willingness to evaluate supplemental efficacy data as a constructive signal for deramiocel's approval prospects even if it delays the original PDUFA timeline.
Outlook
The revised PDUFA timeline, once confirmed, along with the FDA's ultimate decision on deramiocel for Duchenne muscular dystrophy, represent the next major disclosed milestones for Capricor Therapeutics.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.